What 5 Analyst Ratings Have To Say About LAVA Therapeutics
Portfolio Pulse from Benzinga Insights
LAVA Therapeutics (NASDAQ:LVTX) has received 5 analyst ratings in the last quarter, with 2 being bullish and 3 somewhat bullish. The average 12-month price target for the stock is $6.6, a decrease of 26.67% from the previous average of $9.00.
August 23, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
LAVA Therapeutics has received positive analyst ratings, but the average price target has decreased, indicating a potential decrease in stock price.
Analyst ratings are a significant factor in stock performance. While LAVA Therapeutics has received positive ratings, the decrease in the average price target could indicate a potential decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100